BioCentury | Aug 5, 2020
Product Development

I-SPY COVID brings new set of targets to master protocols for acute respiratory distress

While most master protocols for COVID-19 have converged on an overlapping set of experimental therapies, the COVID R&D Alliance’s adaptive trial is kicking off with five therapeutic targets largely untouched in the indication. Three members...
BC Extra | Sep 10, 2019
Financial News

Pharvaris raises $66M series B for clinical development of oral HAE therapy

Pharvaris will use its new $66 million series B round to fund early clinical development of its lead compound, an oral small molecule that could give HAE patients an easier-to-use option than existing injectable therapies...
BC Innovations | May 31, 2018
Emerging Company Profile

Oral route for HAE

The team behind Firazyr icatibant has reunited to develop an oral version of the drug that could give hereditary angioedema patients the alternative to injectables they’ve been asking for. Pharvaris B.V. brings together team members...
BC Extra | May 18, 2017
Clinical News

Shire HAE treatment from Dyax deal clears Phase III hurdle

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will submit a BLA to FDA by early next year for subcutaneous lanadelumab (SHP643) to prevent hereditary angioedema attacks. The company will base its submission on data from the...
BC Innovations | Jan 22, 2015
Targets & Mechanisms

Pseudo-allergy exposed

The perpetual worry for clinicians in administering injectable drugs is the chance they will induce allergic-type reactions either at the site of injection, or systemically if given during surgery. The problem turns out to be...
BC Week In Review | Mar 3, 2014
Clinical News

Firazyr icatibant regulatory update

EMA's CHMP said Shire withdrew an application to extend the label of Firazyr icatibant to treat angioedema caused by the class of drugs known as angiotensin-converting enzyme (ACE) inhibitors. Shire withdrew the application based on...
BC Innovations | Feb 27, 2014
Targets & Mechanisms

The XII factor

Factor XII sits atop one branch of the clotting cascade but has not been pursued for treating and preventing thrombosis because it was seen as a minor player in blood coagulation. Now, a group from...
BioCentury | Nov 18, 2013
Strategy

Shire goes vertical

The proposed $4.2 billion buyout of ViroPharma Inc. fits Shire plc 's long-standing growth through acquisition model, but the new CEO also wants to focus on internal R&D in rare diseases. This deal is an...
BioCentury | Apr 1, 2013
Strategy

Shire sees opportunity

With two ophthalmics deals in as many weeks, Shire plc has revealed the next specialty area in which it wants a foothold. The company believes the small size of the ophthalmic practitioner population - about 42,000...
BC Week In Review | Mar 19, 2012
Clinical News

Firazyr icatibant regulatory update

The Scottish Medicines Consortium recommended the use of Firazyr icatibant from Sanofi on the National Health Service (NHS) in Scotland to treat acute attacks of hereditary angioedema (HAE) in adults - its approved indication. FDA approved...
Items per page:
1 - 10 of 105